Publicacións en colaboración con investigadores/as de University of Milan (32)

2024

  1. Correction to: Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial (Nature Communications, (2024), 15, 1, (5251), 10.1038/s41467-024-49121-3)

    Nature Communications

  2. Correction to: dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe (Nature Communications, (2024), 15, 1, (3736), 10.1038/s41467-024-47751-1)

    Nature Communications

  3. Improved guidance is needed to optimise diagnostics and treatment of patients with thyroid cancer in Europe

    Endocrine, Vol. 83, Núm. 3, pp. 585-593

  4. dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe

    Nature Communications, Vol. 15, Núm. 1

2022

  1. Tackling Thyroid Cancer in Europe—The Challenges and Opportunities

    Healthcare (Switzerland), Vol. 10, Núm. 9

2017

  1. Rewiring of the apoptotic TGF-β-SMAD/NFκB pathway through an oncogenic function of p27 in human papillary thyroid cancer

    Oncogene, Vol. 36, Núm. 5, pp. 652-666

  2. The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis

    Neuroendocrinology, Vol. 105, Núm. 2, pp. 131-140

2005

  1. Consensus statement: Medical management of acromegaly

    European Journal of Endocrinology, Vol. 153, Núm. 6, pp. 737-740

2003

  1. Diagnosis and treatment of acromegaly complications

    Journal of Endocrinological Investigation, Vol. 26, Núm. 12, pp. 1242-1247

2002

  1. Consensus: Guidelines for acromegaly management

    Journal of Clinical Endocrinology and Metabolism

2000

  1. Criteria for cure of acromegaly: A consensus statement

    Journal of Clinical Endocrinology and Metabolism, Vol. 85, Núm. 2, pp. 526-529

1985

  1. Activation of the cholinergic system and growth hormone release in the dog: Functional interactions with other neurotransmitters

    Acta Endocrinologica, Vol. 108, Núm. 1, pp. 36-43

  2. Prolactin in cerebrospinal fluid increases the synthesis and release of hypothalamic γ-aminobutyric acid

    Journal of Endocrinology, Vol. 106, Núm. 3, pp. 323-328

1984

  1. Daily fluctuations in the activity of the tuberoinfundibular GABAergic system and plasma prolactin levels

    Neuroendocrinology, Vol. 39, Núm. 4, pp. 367-370

  2. Regulation of prolactin secretion during suckling: involvement of the hypothalamo-pituitary GABAergic system

    Journal of Endocrinological Investigation: Official Journal of the Italian Society of Endocrinology, Vol. 7, Núm. 5, pp. 481-487

1983

  1. Cholinergic and histaminergic involvement in the growth hormone releasing effect of an enkephalin analog FK 33-824 in man

    Psychopharmacology, Vol. 80, Núm. 2, pp. 120-124

  2. Effect of agonists and antagonists of cholinergic neurotransmission on growth hormone release in the dog

    Acta Endocrinologica, Vol. 103, Núm. 1, pp. 15-20

  3. Opiates and their antagonists modulate luteinizing hormone acting outside the blood brain barrier

    Life Sciences, Vol. 32, Núm. 15, pp. 1751-1756

1981

  1. A role for dopamine in growth hormone regulation in the dog

    Endocrinology, Vol. 108, Núm. 4, pp. 1469-1475

  2. Central nervous system derived GABA influences plasma GABA concentrations and prolactin secretion

    British Journal of Pharmacology, Vol. 72, Núm. 1